On October 3, 2022, Therapeutic Solutions International (TSOI) announced new data suggesting that therapeutic effects of its universal donor stem cell product are mediated in part through CD103-expressing dendritic cells and their exosomes. “While the field of exosome therapeutics is growing exponentially, the use of dendritic cell exosomes for respiratory conditions is completely unheard of.” In a series of experiments, it was found that protection against both chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome (ARDS) could be transferred to naïve mice by dendritic cells expressing the molecule CD103. Furthermore, exosomes, which are nanoparticles produced by cells, were capable of transferring protection to naïve mice.